Barclays
ESPR icon

Barclays’s Esperion Therapeutics ESPR Stock Holding History

Barclays’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-1,000
Closed -$60K – 6217
2019
Q4 		$60K Sell
1,000
-1,900
-66% -$85.4K ﹤0.01% 5684
2019
Q3 		$106K Hold
2,900
– – ﹤0.01% 5436
2019
Q2 		$135K Buy
2,900
+1,800
+164% +$84.5K ﹤0.01% 5450
2019
Q1 		$44K Sell
1,100
-400
-27% -$17.9K ﹤0.01% 5965
2018
Q4 		$69K Sell
1,500
-24,200
-94% -$1.17M ﹤0.01% 5281
2018
Q3 		$1.14M Buy
25,700
+1,800
+8% +$82.6K ﹤0.01% 3501
2018
Q2 		$937K Buy
23,900
+23,500
+5,875% +$1.19M ﹤0.01% 3358
2018
Q1 		$29K Buy
400
+300
+300% +$22K ﹤0.01% 6262
2017
Q4 		$7K Hold
100
– – ﹤0.01% 6595
2017
Q3 		$5K Sell
100
-74,900
-100% -$3.61M ﹤0.01% 6404
2017
Q2 		$3.47M Buy
+75,000
New +$2.76M ﹤0.01% 1759
2015
Q3 		– Sell
-2,500
Closed -$203K – 6884
2015
Q2 		$203K Buy
+2,500
New +$245K ﹤0.01% 4133

Other funds holding ESPR

Allworth Financial
Allworth Financial Folsom, California $28.2B AUM 13.34% 1-Year Est. Return

Barclays's ESPR Position: Q3 2026 in Review

Barclays sold out of Esperion Therapeutics (ESPR) in Q3 2026, closing a stake of 207,293 shares — an estimated $655K sold.

Barclays first reported a position in ESPR in Q3 2013 and held it in 52 quarters. The position peaked at $9.5M in Q2 2020. 2 funds tracked by Wall St. Rank hold ESPR as of Q3 2026.

  • Barclays reported no remaining Esperion Therapeutics position as of Q3 2026 after selling out during the quarter.
  • Barclays sold 207,293 Esperion Therapeutics shares in Q3 2026, an estimated $655K.
  • Barclays first reported a position in Esperion Therapeutics in Q3 2013 and held it in 52 quarters.
  • Barclays's Esperion Therapeutics position peaked at $9.5M in Q2 2020.
  • 2 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q3 2026.

Based on Barclays's 13F filing for Q3 2026, filed 6 Nov 2026.